Synthesis of the evidence on the impact of pre-operative direct oral anticoagulants on patient health outcomes after hip fracture surgery: rapid systematic review

Rebecca J. Mitchell · Sophie Jakobs · Nicole Halim · Hannah Seymour · Seth Tarrant

Abstract

Purpose To synthesise the evidence on the impact of pre-operative direct oral anticoagulants (DOACs) on health outcomes for patients who sustain a hip fracture.

Method A rapid systematic review of three databases (MEDLINE, Embase and Scopus) for English-language articles from January 2000 to August 2021 was conducted. Abstracts and full text were screened by two reviewers and articles were critically appraised. Data synthesis was undertaken to summarise health outcomes examined for DOAC users versus a no anticoagulant group. Key information was extracted for study type, country and time frame, population and sample size, type of DOACs, comparator population(s), key definitions, health outcome(s), and summary study findings.

Results There were 21 articles identified. Of the 18 studies that examined time to surgery, 12 (57.1%) found DOAC users had a longer time to surgery than individuals not using anticoagulants. Five (83.3%) of six studies identified that DOAC users had a lower proportion of surgery conducted within 48 h Four (40.0%) of ten studies reporting hospital length of stay (LOS) identified a higher LOS for DOAC users. Where reported, DOAC users did not have increased mortality, blood loss, transfusion rates, complication rates of stroke, re-operation or readmissions compared to individuals not using anticoagulants.

Conclusions The effect of DOAC use on hip fracture patient health was mixed, although patients on DOACs had a longer time to surgery. The review highlights the need for consistent measurement of health outcomes in patients with a hip fracture to determine the most appropriate management of patients with a hip fracture taking DOACs.

Keywords Direct oral anticoagulant · Hip fracture · Surgery · Complication · Health outcome

Introduction

Sustaining a hip fracture is a serious injury for older adults aged ≥ 65 years, as the injury typically requires surgery, can result in ongoing mobility issues, reduced health-related quality of life (HRQoL) or death [1–4]. Much of the evidence indicates that hip fracture surgery should be performed within 1 or 2 days after hospital admission to achieve the best health outcomes, and reduce hospital length of stay (LOS), the likelihood of complications, and mortality [5–8]. However, many older adults with a hip fracture have underlying chronic comorbid conditions, such as thromboembolic disease or atrial fibrillation, that are managed with antithrombotic medication [9]. Traditionally, the use of vitamin K antagonist (VKA) anticoagulants, such as warfarin, has necessitated reversal of their effects pre-operatively to reduce the patient’s international normalized ratio (INR) which may lead to delayed surgical intervention [10, 11].

Unlike VKAs, the use of direct oral anticoagulants (DOACs), including factor Xa inhibitors (i.e., apixaban, rivaroxaban, edoxaban) and a direct thrombin inhibitor (i.e., dabigatran), has the benefit of predictable pharmacokinetics without the need for regular monitoring [10]. However, the use of DOACs has resulted in acknowledged variations in practice in relation to health utilisation outcomes, such as...
time to surgery, after a hip fracture [10, 12]. While national clinical guidelines recommend hip fracture surgery within 48 h of hospital admission [13–15], there are few consistent guidelines around the pre-fracture use of DOACs and hip fracture surgery.

It is unclear whether the timing of surgical intervention for hip fracture patients prescribed DOACs adversely affects patient or health utilisation outcomes, such as blood loss or hospital LOS, respectively. Any delay to surgery needs to be balanced against potential increased risk of patient complications such as delirium, infection or thromboembolism. The HIP ATTACK study demonstrated that operating within 6 h of presentation with a hip fracture had no detrimental effect and was associated with a lower risk of delirium, urinary tract infection, and moderate to severe pain scores on days 4–7 compared to standard care [16]. Early surgery in HIP ATTACK led to faster mobilisation, a shorter hospital LOS and no difference in mortality compared to usual care [16].

Surgical delays to allow medical optimisation of patients taking pre-fracture anticoagulation treatment aim to reduce intra- and post-operative blood loss [17] and may be necessary to deliver safe regional anaesthesia [18]. As the use of DOACs is increasing among older adults [19], and with the number of hip fractures worldwide estimated to rise to 6.26 million by 2050 [20], whether there is evidence of a detrimental effect on health outcomes of older adults taking DOACs pre-operatively needs to be collated and synthesised. The aim of this systematic rapid review is to synthesise the current evidence on the impact of pre-operative DOACs on patient health outcomes for patients who sustain a hip fracture. This will inform future research, audit and guideline development.

Methods

This rapid systematic review synthesises the evidence on the impact of pre-operative DOACs on the health outcomes of older adults who underwent hip fracture surgery. The review records the type of DOACs examined, whether any comparator population(s) were included, the type of primary and secondary health outcomes examined, and summarises the findings of each study.

Definitions

Research articles were included in the rapid review if they examined health outcomes of patients who underwent hip fracture surgery. Articles were included if the population in the studies was primarily aged ≥ 60 years, was admitted to hospital after a hip fracture (e.g. intracapsular, trochanteric or subtrochanteric), and underwent surgery for the hip fracture (e.g. intramedullary nail or hip screw, hemiarthroplasty, total hip replacement).

The research articles included had to evaluate the impact of pre-operative DOACs (i.e., rivaroxaban, apixaban, dabigatran, edoxaban) on patient health outcomes. Comparator populations could include patients not taking DOACs, patients taking VKAs (e.g., warfarin) or patients taking oral platelet inhibitors (PAIs) (e.g., aspirin, clopidogrel, ticagrelor).

Patient health outcomes included those relating to healthcare utilisation, such as time to surgery, mortality, hospital LOS, intensive care unit (ICU) LOS, blood loss, need for a blood transfusion, or post-operative complications (e.g., infection, bleeding, pulmonary embolism, deep vein thrombosis). For the purposes of this rapid review, measures of health outcomes related to life post-discharge, such as mental health, HRQoL, or ability to perform activities of daily living (ADLs), were excluded.

Data sources and eligibility criteria

A systematic search was conducted using three databases: MEDLINE, Embase, and Scopus. The search strategy was developed with a university librarian and included the following search terms: (anticoagulant* OR ‘oral anticoagulant’ OR ‘DOAC*’ OR Rivaroxaban OR Apixaban OR Dabigatran OR Edoxaban) AND ABS (‘hip fracture’ OR ‘hip surgery’) AND (postoperative* OR mortality OR ‘time to surgery’ OR ‘length of stay’ OR ‘complication*’ OR bleed* OR ‘blood loss’ OR embolism OR thrombosis OR ‘intensive care*’) (see Appendix 1 for full search strategy).

Articles were excluded if patients did not have surgery after their hip fracture, patients were not taking DOACs pre-operatively (other than comparator populations), if the article was a systematic review, other type of review, a single case report, a study protocol, or if there was insufficient detail regarding the health outcome(s) examined. Results were limited to English-language articles that were published in peer-review journals from 1 January 2000 to 31 August 2021. Snowballing of article reference lists and review of co-author repositories was conducted to identify any potential articles not previously identified.

Abstract screening

The full citation information including title and abstract of each article identified during the database searches was imported into Endnote X20 and duplicates removed. The abstracts were independently assessed for inclusion by two reviewers (SJ, NH), who met regularly to discuss any uncertainties. If the abstract did not report that the research evaluated the impact of pre-operative DOACs on patient health outcomes after hip fracture surgery it was excluded. Both
Full-text screening, data extraction and quality review

The full text of each article was assessed by two reviewers (SJ, NH), if the article was included in the abstract review stage. Any article that did not meet the inclusion criteria was excluded. For articles that met the inclusion criteria, key information was extracted from each article during the full-text review by two reviewers (SJ, NH), including; authors and publication year; review objective/aim; study type, country and time frame examined, population and sample size, type of DOACs examined, comparator population(s), health outcome(s), and summary study findings. Data extraction results were independently appraised for accuracy by a third author (RM). The methodological quality of the articles was assessed by two reviewers (SJ, NH) and appraised by a third reviewer (RM) using the Critical Appraisal Skills Programme (CASP) cohort [21] or case–control [22] study checklists, where applicable. The quality of retrospective matched case-comparison studies was assessed with the case–control study checklist. Any clarifications regarding methodological quality were discussed between reviewers.

Data synthesis

The information on the included studies in the data extraction table was compared and a data synthesis was undertaken by one reviewer (RM) and appraised by two reviewers (HS and ST). The data synthesis involved identifying the most common health outcomes examined for DOAC users versus the no anticoagulant use comparator group. The findings for each health outcome were summarised as to whether DOAC users had a worse outcome than a no anticoagulant comparator population, where possible. The data extraction and data synthesis results were examined by two authors (HS and ST) and whether any recommendations could be made regarding the pre-operative use of DOACs and the timing of hip fracture surgery based on the existing research evidence was considered (Supplementary Table 1).

Results

A total of 318 articles were identified during the database searches. After removing duplicates, 233 articles remained. After abstract review, 34 full-text articles were examined, along with 11 articles from snowballing. A final 21 articles were included in the rapid review (Fig. 1).

Study type, country and comparator population

Around three-quarters (76.2%) were retrospective cohort studies, with five (23.8%) case–control/comparison designs. The number of patients taking DOACs in the studies ranged from 11 to 1063, with a median of 33 patients. Three (14.3%) studies each were conducted in Australia, the United Kingdom (UK), Israel, and the United States (US), two (9.5%) each in Canada, Germany and Norway, and one (4.8%) study each in Austria, Denmark and Italy. Ten (47.6%) studies used two comparison groups, seven (33.3%) used one comparison group, two (9.5%) studies used three comparison groups and two (9.5%) studies used four comparison groups. The comparison groups involved patients not taking any anticoagulants pre-surgery (n = 18 groups), patients taking VKAs (n = 14 groups), and patients taking PAs (n = 7 groups).

Patient age and common health outcomes

The age inclusion criteria varied for patients, eight (38.1%) studies included patients aged ≥ 65 years, four (19.0%) studies included patients aged ≥ 60 years, one (4.8%) study included patients aged > 70 years, five (23.8%) studies did not specify their patient age inclusion criteria, but the mean age of patients in these studies was in the mid-80 s. Where indicated, the mean patient age ranged from 80.7 to 85.0 years and median age ranged from 83.5 to 86.0 years (Table 1).

The most common health outcomes examined were time to surgery (100%), mortality (95.2%; n = 20), blood loss (76.2%; n = 16), post-operative complications (52.4%; n = 11) and hospital LOS (47.6%; n = 10). Type of anaesthesia used during surgery was only recorded in five (23.8%) studies. Information regarding when DOAC use ceased prior to surgery was not often recorded (9.5%; n = 2).

Time to surgery

Time to surgery (either exact or within < 48 h) was not defined in six (30.0%) studies. Of the 18 studies that examined exact time to surgery, 12 (57.1%) identified that DOAC users had a longer time to surgery, 5 (23.8%) found no difference in time to surgery, and 1 (4.8%) study identified a longer time to surgery for closed reduction internal fixation, but not for hemiarthroplasty compared to patients not using anticoagulants prior to surgery. Five (83.3%) of six studies identified that DOAC users had a lower proportion of surgeries conducted within 48 h compared to patients not using anticoagulants.
Blood loss and transfusions

Blood loss definitions varied and none of the nine studies that reported blood loss found a difference in blood loss between patients using DOACs versus no anticoagulants. Only 2 (18.2%) of the 11 studies that reported on the proportion of transfusions between DOACs compared to patients not using anticoagulants found a higher proportion of blood transfusions for patients using DOACs.

Post-operative complications and hospital LOS

No difference was found in post-operative complication rates for the eight studies that reported on complications and no difference was found for the three studies that reported on the incidence of stroke between DOAC users and patients not using anticoagulants. One (50.0%) of two studies that reported on wound ooze (defined as clinically identified ooze with or without bleeding) found a higher proportion of ooze for DOAC users versus patients not using anticoagulants. One (14.3%) of the seven studies that reported on re-operations/readmissions identified a higher proportion of readmissions for DOAC users, compared to patients not using anticoagulants. Four (40.0%) of the ten studies that reported on hospital LOS identified a higher LOS for DOAC users.

Mortality

Seven (87.5%) of 8 studies that reported in-hospital mortality, 12 (92.3%) of 13 studies that reported 30-day mortality, and 6 (85.7%) of 7 studies that reported mortality at 1-year identified no difference in mortality rates for DOAC users compared to patients not using anticoagulants. One (14.3%) study identified a higher 1-year mortality for DOAC users for closed reduction internal fixation, but not for hemiarthroplasty compared to patients not using anticoagulants.

Quality assessment

Methodological quality assessment measures for articles varied and few studies (38.1%; n = 8) received all ‘Yes’ ratings (Tables 2 and 3).

CASP Appraisal Checklist questions

1. Did the study address a clearly focussed issue?  
2. Was the cohort recruited in an acceptable way?  
3. Was the exposure accurately measured to minimise bias?  
6b. Was the follow-up of subjects long enough?  
7. What are the results of this study?  
8. How precise are the results?
Table 1 Characteristics of studies examining the impact of DOACs on patient health outcomes after hip fracture surgery

| Authors and publication year | Objective/aim | Study type | Country/study time frame | DOAC(s) examined (number of patients by drug) | Comparison population(s) | Population and sample size |
|------------------------------|---------------|------------|--------------------------|-----------------------------------------------|---------------------------|----------------------------|
| Bruckbauer et al. 2019 [48]  | To assess the impact of DOAC intake compared with coumadin (COU) in hip fracture (HF) patients | Retrospective cohort | Salzburg, Austria Jan 2015–May 2017 | Any DOAC (n=13 dabigatran, n=34 rivaroxaban, n=7 apixaban) | 1. COU | Patients ≥ 65 years with a median age of 83.5 years [range 76–89] n=54 DOAC; n=59 COU; n=207 no-ATT |
| Cefaro et al. 2019 [49]     | To establish TTS among non-anticoagulated and anticoagulated patients taking either vitamin K antagonist (VKA) or DOACs | Retrospective cohort | Canada, 1 July 2016–31 Dec 2017 | Any DOAC (n=6 dabigatran, n=21 apixaban, n=4 rivaroxaban) | 1. VKA | Patient inclusion was ≥ 18 years, but mean age was 84 years [range 29–98] n=31 DOAC; n=28 VKA; n=413 no anticoagulant |
| Creeper et al. 2020 [50]    | To investigate the effect of DOAC therapy on time to surgery and patient outcomes, and to explore the impact of different pre-operative protocols on surgical delay | Retrospective cohort | Australia, 1 Jan 2017–31 Dec 2017 | Any DOAC (n=8 dabigatran, n=44 apixaban, n=29 rivaroxaban, n=1 edoxaban) | 1. Warfarin 2. antiplatelets 3. dual anticoagulation and antiplatelet 4. no anticoagulation or antiplatelet | Patient inclusion age was not specific, but median age was 84 years [interquartile range: 76–89] n=82 DOACs; n=63 warfarin; n=366 antiplatelets; n=13 dual anticoagulation and antiplatelet; n=714 no anticoagulation or antiplatelet |
| Daugaard et al. 2019 [47]   | To examine if pre-operative antithrombotic treatment was associated with increased use of blood transfusion and 30-day mortality following hip fracture surgery | Retrospective cohort | Denmark, 1 Jan 2005–31 Dec 2016 | Any DOAC—both current (i.e., at least one prescription ≤90 days prior to surgery) and former (i.e., redemption of one prescription 91–365 days prior to surgery) users (unspecified number by DOAC type) | 1. VKA 2. antiplatelets including acetylsalicylic acid 3. non-user of DOACs in the year prior to surgery | Patients ≥ 65 years. Mean age not specified n=1063 DOAC, n=4162 VKA, n=24,567 antiplatelets; n=73,507 non-DOACs |
| Franklin et al. 2018 [37]   | To evaluate the pre-hospital use of DOACs on the outcomes of early surgical fixation of geriatric HF | Retrospective case–control | US, 2010–2015 | Any DOAC (n=6 rivaroxaban, n=5 apixaban n=8 dabigatran) | 1. Controls (unspecified criteria, but excluded patients on plavix or coumadin or >81 mg of daily aspirin) matched on age ≥ 3 years, sex, and operation type (i.e., hemiarthroplasty, cephalomedullary nail (CMN), sliding hip screw | Patients aged 60–89 years who underwent HF surgery within 48 h of admission. Mean age not specified n=19 DOACs n=76; controls |
| Frenkel Rutenberg et al. 2018 [51] | To assess outcomes of patients treated with VKAs or DOACs undergoing surgical treatment for fragility HF | Retrospective cohort | US, Jan 2012–Jun 2016 | Any DOAC (n=18 dabigatran, n=16 rivaroxaban, n=13 apixaban) | 1. VKAs 2. no-anticoagulation | Patients > 65 years with a mean age –82 years n=47 DOACs; n=103 VKAs; n=646 no anticoagulation |
| Gosch et al. 2020 [52]      | To compare the short-term outcome of older hip fracture patients without oral anticoagulation, VKAs and DOACs | Retrospective case–control | Germany, Feb 2017–Jun 2018 | Any DOAC (unspecified DOAC type) | 1. No anticoagulants 2. VKA | Patients > 70 years Patient mean age was 83.9 years n=26 DOACs, n=15 VKA; n=61 no anticoagulants |
| Hourston et al. 2020 [42]   | To assess whether HF patients admitted on Warfarin or DOACs were at risk of operative delay, prolonged LOS, or increased mortality | Retrospective cohort | UK, Oct 2014–Dec 2016 | Any DOAC (n=19 rivaroxaban, n=8 apixaban, n=5, dabigatran) | 1. No anticoagulants 2. Warfarin | Inclusion age unspecified Patient mean age was 85 years n=32 DOAC, n=83 warfarin, n=729 no anticoagulants |
| King et al. 2020 [38]       | To investigate the effect of DOACs on patient outcomes receiving early (<48 h) versus delayed (>48 h) HF surgery | Retrospective cohort | Queensland, Australia; Jan 2012–Dec 2017 | Any DOAC (n=5 apixaban, n=8 dabigatran, n=15 rivaroxaban) | 1. No DOACs matched to TTS < 48 h on age, ASA grade, sex, surgery type (i.e., arthroplasty vs. other fixation); time to surgery (<48 h) and dementia status | Inclusion age unspecified Mean age ≥ 84 years n=28 DOAC (n=17 early surgery and n=11 late surgery), n=36 no DOACs |
### Table 1 (continued)

| Authors and publication year | Objective/aim | Study type | Country/study time frame | DOAC(s) examined (number of patients by drug) | Comparison population(s) | Population and sample size |
|-----------------------------|---------------|------------|--------------------------|---------------------------------------------|--------------------------|-----------------------------|
| Leer Salvesen et al. 2020   | To determine whether DOAC users have delayed HF surgery compared to non-DOAC users and whether hospital LOS, mortality, re-operations and bleeding complications were influenced by use of DOACs | Retrospective cohort | Norway, Dec 2016–Dec 2017 | Any DOAC (unspecified number by DOAC type) | 1. No anticoagulants | Patients aged > 60 years, with a mean age of 82.1 years |
| Lott et al. 2019            | To evaluate whether patients with HFs receiving platelet aggregation inhibitors (PAI) and DOACs treated within 48 h of admission had worse surgical and clinical outcomes than those whose surgery was delayed > 48 h | Retrospective cohort | US, Oct 2014–Sep 2016 | Any DOAC (n = 4 dabigatran, n = 10 rivaroxaban, n = 15 apixaban) | 1. PAI including clopidogrel and aspirin | Patients ≥ 55 years. However, mean age was ~ 83 years |
| Mahmood et al. 2021         | Review whether taking PAIs or anticoagulants was associated with increased mortality for HF patients; and to evaluate the mortality and complication rates for patients taking these agents who underwent early (< 24 h) surgery | Retrospective cohort | UK, Jan 2016–Jan 2019 | Any DOAC (unspecified number by DOAC type) | 1. Control group (no PAI or anticoagulants) 2. PAI (i.e., aspirin or clopidogrel) 3. Warfarin | Patients aged ≥ 60 years with a mean age of 82.1 years |
| Mullins et al. 2018         | To determine whether not waiting for the elimination of DOACS has an effect on the amount of peri-operative bleeding in HF patients | Retrospective case–control | UK, Jan 2015–March 2017 | Any DOAC (n = 14 apixaban, n = 5 dabigatran, n = 44 rivaroxaban) | 1. Patients not taking DOACS or warfarin (matched on age ± 5 years, sex, operation) American Society of Anesthesiologists (ASA) grade | Patients aged ≥ 60 years with a mean age of 85 years |
| Rostagno et al. 2021        | To investigate the effects of ongoing treatment with DOACs on TTS and on in-hospital clinical outcomes in patients with HF | Retrospective case–control | Italy, Jan 2016–Jan 2019 | Any DOAC (n = 28 dabigatran, n = 19 rivaroxaban, n = 23 apixaban, n = 3 edoxaban) | 1. Patients not taking anticoagulants (matched on age, sex, fracture type, ASA grade) | Elderly patients, age unspecified. Mean age was ~ 84 years |
| Saliba et al. 2020          | Assess the association between pre-operative DOACs use and adverse outcomes in elderly patients with HF | Retrospective cohort | Israel, 1 Jan 2014–31 Dec 2018 | Any DOACs (n = 129 apixaban, n = 71 rivaroxaban, n = 47 dabigatran) | 1. VKAs 2. no anticoagulants | Patients ≥ 65 years with a mean age of 82.2 years |
| Scherman et al. 2019        | To compare estimates of peri-operative blood loss and mortality between HF patients taking DOACs and no anticoagulation | Retrospective cohort | Israel, 2011–2016 | Any DOAC (apixaban, rivaroxaban and dabigatran, unspecified number by DOAC type) Could have concurrent use of aspirin and PAI (clopidogrel, prasugrel, ticagrelor) | 1. control with no anticoagulant use 2. Coumadin | Patients ≥ 65 years who had closed reduction internal fixation (CRIF) or hemiarthroplasty (HA) with a mean age ~ 82 years |
| Schuetz et al. 2019         | To determine the effect of DOACs on HF patients which received a proximal femur nail anti-rotation (PFNA) within 24 h after trauma | Retrospective cohort | Germany, Jan 2015–Dec 2017 | Any DOACs (unspecified number by DOAC type) | (1) no anticoagulation; (2) acetylsalicylic acid (ASS); (3) PAI; (4) VKA | Patients of all ages, but mean age was 80.7 years |
| Authors and publication year | Objective/aim | Study type | Country/study time frame | DOAC (s) examined (number of patients by drug) | Comparison population(s) | Population and sample size |
|-----------------------------|--------------|------------|--------------------------|----------------------------------------------|--------------------------|------------------------------|
| Shani et al. 2021 [53]      | To investigate if patients treated with DOACs have delayed HF surgical compared to patients on no anticoagulants or Warfarin, and if there is an impact on TTS, LOS and mortality | Retrospective cohort | Israel, 1 Jan 2014–31 Dec 2017 | Any DOAC (unspecified number by DOAC type) | 1. No oral anticoagulant; 2. Warfarin | Patients > 65 years with a mean age of ~83 years, n = 415 DOACs; n = 5,102 no anticoagulants; and n = 311 warfarin |
| Tarrant et al. 2020 [39]    | To investigate how DOACs affect surgical timing and peri-operative outcomes | Retrospective case–control | Australia; 2011–2018 | Any DOACs (n = 56 apixaban, n = 18 dabigatran, n = 38 rivaroxaban) | 1. Control group not taking antithrombotic medication and matched on age, sex, and year of admission | Patients aged ≥ 65 years, with a mean age of 84.3 years, n = 112 DOACs; n = 112 controls |
| Tran et al. 2015 [54]       | To determine how anticoagulation with VKA or DOAC affects TTS | Case–control | Canada, 1 Jan 2010–24 March 2014 | Any DOAC (n = 22 dabigatran, n = 4 rivaroxaban, n = 1 apixaban) | 1. VKAs 2. No anticoagulants matched on age and sex | Age inclusion criteria not specified, but median age 86 years, n = 27 DOACs; n = 260 no anticoagulants; n = 233 VKAs |
| Viktil et al. 2019 [55]     | To determine serum concentrations and elimination rates of DOACs in HF patients and TTS | Prospective cohort pilot study | Oslo, Norway (6-month period, dates unspecified) | Any DOAC (n = 2 dabigatran, n = 3 rivaroxaban, n = 6 apixaban) | 1. Warfarin 2. PAI | Patients ≥ 65 years, with a median age of 84 years, n = 11 DOACs; n = 14 warfarin; n = 50 PAI |

| Authors and publication year | Blood loss definition | Time to surgery definition | Type of anaesthesia | Hours prior to surgery DOACs ceased | Use of reversal agents | Health outcome(s) examined (primary and secondary outcomes) | Study findings (primary and secondary) |
|-----------------------------|-----------------------|---------------------------|---------------------|-----------------------------------|----------------------|--------------------------------------------------------|-------------------------------------|
| Bruckbauer et al. 2019 [48] | Drainages from intensive care unit (ICU) admission to discharge | Time from admission to surgery | NR | NR | Specified in secondary study findings | Primary: (1) transfusion requirements; (2) post-operative bleeding rate Secondary: (1) time to surgery (TTS); (2) use of reversal agents; (3) intensive care unit (ICU) length of stay (LOS); (4) mortality | Primary: (1 and 2) no difference in blood less through drainages for DOAC or COU Secondary: (1) TTS longer for DOAC group: 3% on DOACs, 51% on COU, and 55% no-ATT had surgery within 24 h (2) Reversal agents: 78% on COU received vitamin K and 4 patients received PCC One patient on DOAC received prothrombin complex concentrate (PCC) and one patient on dabigatran received idarucizumab (3) No differences in ICU LOS (4) No differences for in-hospital mortality |
| Authors and publication year | Blood loss definition | Time to surgery definition | Type of anaesthesia | Hours prior to surgery DOACs ceased | Use of reversal agents | Health outcome(s) examined (primary and secondary outcomes) | Study findings (primary and secondary) |
|------------------------------|-----------------------|---------------------------|--------------------|-----------------------------------|-----------------------|------------------------------------------------|------------------------------------------------|
| Cafaro et al. 2019 [49]      | International Society on Thrombosis and Haemostasis (ISTH) Any major bleeding from presentation to discharge including surgical bleeding Pre-operative major bleeding limited to the pre-operative period | Time from hospital admission to surgery | NR                 | NR                               | Peri-operative use of PCC, vitamin K, idarucizumab and/or plasma, unspecified further | Primary: (1) TTS Secondary: (1) surgical delay; (2) hospital LOS; (3) acute venous thromboembolism (VTE), pulmonary embolism PE; (4) any major bleeding and pre-operative major bleeding; (5) stroke; (6) in-hospital mortality | Primary: (1) Median TTS was longer in VKA (64 h) and DOAC (61 h) vs. no anticoagulant (44 h). No difference in TTS for VKA (64 h) vs. DOAC (61 h) Secondary: (1) No VKA and 39% of DOACs had surgery within 48 h vs. 60% no anticoagulant (2) Similar LOS for VKA, DOAC and no anticoagulant; 15.6, 16.1, 16.6 days, respectively (3) No difference in VTE or PE for no anticoagulant, VKA or DOAC (4) No difference in any major bleeding for DOAC (80.0%) vs. VKA (75.0%) vs. no anticoagulant (84.9%) Pre-operative major bleeding higher in DOAC (24.0%) vs. VKA (14.2%) vs. no anticoagulant (10.0%) (5) No difference in stroke between groups (6) No difference in in-hospital mortality for DOAC (6.5%), VKA (7.1%) and no anticoagulant (3.4%) |
| Creeper et al. 2020 [50]     | Change in haemoglobin (Hb) (g/L) defined as the difference between the maximum recorded Hb level up to 48 h pre-operatively to the minimum level recorded within 72 h post-operatively | Time of first presentation to any hospital (regardless of location and ability to perform correctional surgery) to the time of operation | NR                 | NR                               | NR                               | Primary: (1) TTS Secondary: (1) post-operative change in haemoglobin; (2) transfused packed red blood cell units 2 days pre-operatively to 3 days post-operatively; (3) 30-day mortality | Primary: (1) median TTS was longer for DOAC (43.9 h) vs. warfarin (27.9 h) and TTS for DOACs vs. other comparator populations was not conducted Secondary: (1) there was no difference in change in haemoglobin between DOAC vs. warfarin and change in haemoglobin for DOACs vs. other comparator populations was not conducted (2) There was no difference in transfusion requirements between DOAC vs. warfarin and transfusion requirements for DOACs vs. other comparator populations was not conducted (3) There was no difference in 30-day mortality for DOAC vs. warfarin and comparison of 30-day mortality for DOACs vs. other comparator populations was not conducted |
| Authors and publication year | Blood loss definition | Type of anaesthesia | Hours prior to surgery DOACs ceased | Use of reversal agents | Health outcome(s) examined (primary and secondary outcomes) | Study findings (primary and secondary) |
|-----------------------------|----------------------|---------------------|-----------------------------------|-----------------------|---------------------------------------------------------------|-------------------------------------|
| Daugaard et al. 2019 [47]   | NR                   | Time from hip fracture admission to surgical procedure | NR                           | NR                    | Primary: (1) red blood cell transfusion within 7 days (2) 30-day mortality Secondary: (1) transfusion and TTS; (2) 30-day mortality and TTS | Primary: (1) compared to non-DOAC users, current DOAC users had a 7% higher adjusted relative risk of a blood transfusion and former DOAC users had no higher transfusion risk (2) Compared to non-DOAC users, both current and former DOAC users had no higher risk of mortality Secondary: (1) compared to non-DOAC users, current DOAC users who had surgery < 24 h had a 14% higher risk of a blood transfusion, and there was no difference for current DOAC users who had surgery between 24 and 36 h or > 36 h. There was no difference for former DOAC users that had surgery < 24 h, between 24-36 h or > 36 h compared to non-DOAC users (2) Compared to non-DOAC users, current and former DOAC users who had surgery < 24 h, between 24 and 36 h or > 36 h. Did not have a higher 30-day mortality compared to non-DOAC users |
| Franklin et al. 2018 NR [37]| NR                   | One DOAC and three controls received spinal anaesthesia as an adjunct to general endotracheal anaesthesia. One control received spinal anaesthesia with MAC sedation. Otherwise all had general endotracheal anaesthesia without adjuncts | Mean (SD) estimated time between most recent ingestion and surgery = 39.5 (14.7) hours | NR                    | Peri-operative outcomes: (1) estimated blood loss (EBL) (mL) (2) transfusion rate (3) TTS (h) Post-operative outcomes: (4) LOS (5) Peri-operative complications, including haematoma formation, persistent serous drainage, thromboembolic events, or need for re-operation (6) Readmission rate (7) in-patient, 30-day, 90-day, and 1-year survival | Peri-operative outcomes: (1 and 2) no difference for EBL, transfusion rates, or blood volume transfused (3) DOACs (28.9 h) within 48 h of admission had longer TTS than controls (21.4 h) Post-operative outcomes: (4, 5) No difference in LOS or peri-operative complication rates (6) DOACs (21%) readmitted at higher rate vs. controls (5.3%) (8) No difference in survival in in-patient, 30 days, 90 days, or at 1 year. Survival at 1 year was DOAC (70.6%) vs. controls (59.1%) |
Table 1 (continued)

| Authors and publication year | Blood loss definition | Time to surgery definition | Type of anaesthesia | Hours prior to surgery DOACs ceased | Use of reversal agents | Health outcome(s) examined (primary and secondary outcomes) | Study findings (primary and secondary) |
|------------------------------|-----------------------|-----------------------------|---------------------|-------------------------------------|-----------------------|-------------------------------------------------------------|----------------------------------------|
| Frenkel Rutenberg et al. 2018 [51] | Need for blood transfusion during hospitalisation | Time from admission to surgery | NR | NR | NR | Primary: (1) in-hospital and 1-year mortality | Secondary: (1) TTS within 48 h; (2) complication (e.g. infection, cardiovascular, pulmonary, renal, neurological, thromboembolic); (3) blood transfusions; (4) readmission within 1 year |
| Gosch et al. 2020 [52] | Major bleeding defined as decrease in haemoglobin level of 2 g per decilitre or more over a 24 h period, transfusion of ≥ 2 units of packed red cells, bleeding at a critical site (intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome or retroperitoneal) or fatal bleeding | NR | NR | NR | NR | Primary: (1) in-hospital mortality; (2) TTS; (3) LOS; (4) ICU and ICU LOS; (5) place of discharge; (6) mobility; (7) complications (incl revision surgery, wound infections, urinary tract infection, pneumonia, myocardial infarction, stroke, thromboembolic events, falls during hospital stay, minor and major bleeding, delirium); (8) blood loss; (9) need for packed red cells, thrombocytes, prothrombin complex concentrate, fresh frozen plasma | Primary: (1) no difference in hospital mortality for DOAC (3.8%) vs. VKA (20%) or no anticoagulants (9.8%) (2) TTS longer for DOAC (42.7 h) vs. no anticoagulants (30 h), but no difference to VKA (40.5 h); (3) LOS longer for DOAC (17.2 days) vs. no anticoagulants (12.6 days) but no difference to VKA (14.4 days); (4) no difference in ICU and ICU LOS between DOACs vs. VKA or no anticoagulants; (5) no difference in discharge location; (6) no difference in mobility at discharge; (7) no difference in any complications, except for minor bleeding, which was higher for VKA (33.3%) vs. no anticoagulants (6.6%), but no difference to DOAC (19.2%); (8) no difference in decrease of haemoglobin; (9) no difference in need for packed red cells |
| Authors and publication year | Blood loss definition | Time to surgery definition | Type of anaesthesia | Hours prior to surgery DOACs ceased | Use of reversal agents | Health outcome(s) examined (primary and secondary outcomes) | Study findings (primary and secondary) |
|------------------------------|-----------------------|---------------------------|-------------------|-----------------------------------|----------------------|---------------------------------------------------------------|-------------------------------------|
| Hourston et al. 2020 [42]    | NR                    | Time from admission to theatre | NR                | NR                                | None used            | Primary: (1) TTS; (2) LOS; (3) 30-day; 6- and 12-month mortality | Primary: (1) TTS longer for DOAC (29 h) vs. warfarin (27 h) and no anticoagulants (22 h). DOAC not associated with increase in TTS > 48 h. Subgroup analysis found apixaban and dabigatran associated with delay > 36 h, but not rivaroxaban. None were associated with a delay > 48 h. (2) No difference for LOS. (3) Warfarin (22%) lower 30-day survival, but not DOACs (6%) or no anticoagulation (4%). No difference for 6- or 12-month mortality. |
| King et al. 2020 [38]        | Measured as greatest haemoglobin value minus lowest haemoglobin value from admission to post-operative day 2 | Time from hospital admission to surgery | NR                | NR                                | NR                   | Primary: (1) Blood transfusion rates; (2) peri-operative blood loss; (3) acute and total LOS; (4) TTS; (5) 30- and 90-day mortality; (6) re-operation; (7) haematoma rates | Primary: (1) no difference in blood transfusion rates. (2) No difference in peri-operative blood loss. (3) No difference in acute or total LOS. (4) TTS longer for early DOAC (32.2 h) than no DOAC (26.0 h). (5) No difference in 30-day mortality. However, late DOAC (36.4%) had higher 90-day mortality vs. early DOAC (9%). (6) No difference in re-operation. (7) Nil haematomas. |
| Leer Salvesen et al. 2020 [43] | Intra-operative blood loss estimated by the surgical team. Blood transfusions for patients with Hb < 9 g/dL and collected from medical records | Time from admission to surgery | General anaesthesia (n = 22 DOACs; n = 10 no anticoagulants). Spinal anaesthesia (n = 25 DOACs; unspecified for anticoagulants) | NR                | NR                   | Primary: (1) TTS; (2) LOS. Secondary: (1) in-hospital, 30-day and 6-month mortality; (2) readmission within 30 days and 6 months; (3) Blood loss during surgery; (4) blood transfusions; (5) wound ooze | Primary: (1) No difference TTS DOAC (28.9 h) vs. no anticoagulants (26.1 h). (2) No difference in LOS DOAC (6.6 days) vs. no anticoagulants (6.1 days). Secondary: (1) No difference in in-hospital (4.3% vs. 3.4%), 30-day (10.6% vs. 12.7%) or 6-month (23.4% vs. 22.1%) mortality for DOAC vs. no anticoagulants, respectively. (2) No difference in 30-day or 6-month readmission. (3) No difference in mean blood loss during surgery. (4) No difference in transfusion rates. (5) Wound ooze higher for DOACs (26%) vs. no anticoagulant (5%). |
| Authors and publication year | Blood loss definition | Time to surgery definition | Type of anaesthesia | Hours prior to surgery DOACs ceased | Use of reversal agents | Health outcome(s) examined (primary and secondary outcomes) | Study findings (primary and secondary) |
|-----------------------------|------------------------|---------------------------|---------------------|-----------------------------------|-----------------------|---------------------------------------------------------------|-----------------------------------------------|
| Lott et al. 2019 [12]       | Surgical blood loss    | Early: surgery within 48 h of presentation; or delayed: surgery > 48 h of presentation | General anaesthesia; spinal anaesthesia, unspecified by DOAC or PAI group | NR | NR | Primary: (1) length of surgery; (2) blood loss during surgery (mL); (3) transfusion requirement; (4) complications (i.e., sepsis, pneumonia, DVT/PE, acute myocardial infarction, acute kidney injury, stroke, surgical site haematoma, decubitus ulcer, urinary tract infection, acute respiratory failure, acute anaemia, cardiac arrest, and inpatient mortality); (5) transfer to ICU/step-down unit | Primary: (1) no difference for surgery length for DOACs or PAIs; (2) no difference for blood loss for DOACs or PAIs; (3) no difference for transfusions for DOACs or PAIs; (4) no difference for DOACs or PAIs for complications for those treated within 48 h or > 48 h of admission; (5) no difference for ICU transfers for patients treated within 48 h or > 48 h (unspecified ICU transfers by DOACs or PAIs) |
| Mahmood et al. 2021 [40]   | Hb levels on admission and the first post-operative day to calculate post-operative Hb drop | Early (i.e., within 24 h of admission) or late (> 24 h of admission) | Aspirin, clopidogrel, DOACs were stopped on admission and surgery was advocated within 36 h, unless patient needed further optimisation or medical workup | Warfarin stopped on admission and 10 mg of intravenous vitamin K given; and INR checked at 6 h. If level > 1.5 further intravenous vitamin K given | Primary: (1) TTS; (2) mortality at 30-days and 1 year; (3) post-operative Hb drop; (4) transfusion rate; (5) wound ooze; (6) infection rate (i.e., prescribed antibiotics); (7) re-operation rate | Primary: (1) no difference in mean TTS (hrs): control (23.5); PAI (24.4); warfarin (29.6); DOAC (28.1) (2) Difference in 30-day mortality: control (4.8%); PAI (12.6%); Warfarin (7.0%); DOAC (9.5%) and 1-year mortality: control (22.4%); PAI (32.3%); warfarin (29.3%); DOAC (29.0%) (3) No difference in post-operative Hb. However sub-group analysis showed difference for DOAC group for TTS < 24 h (20.1 g/L) vs. TTS > 24 h (14.7 g/L) (4) Difference in transfusion rate: control (21.6%); PAI (32.3%); Warfarin (21.7%); DOAC (23.2%) (5) Difference in wound ooze: control (22.2%); PAI (26.9%); warfarin (40.2%); DOAC (24.6%). Sub-group analysis showed difference for PAI group for TTS < 24 h (30.4%) vs. TTS > 24 h (18.4%) and Warfarin group for TTS < 24 h (27.5%) vs. TTS > 24 h (50.0%) (6) No difference in infection rates: control (1.0%); PAI (0.8%); warfarin (0%); DOAC (2.9%) (7) No difference in re-operation rates: control (0.6%); PAI (0.8%); warfarin (0%); DOAC (2.9%) |
| Authors and publication year | Blood loss definition | Time to surgery definition | Type of anaesthesia | Hours prior to surgery DOACs ceased | Use of reversal agents | Health outcome(s) examined (primary and secondary outcomes) | Study findings (primary and secondary) |
|-----------------------------|-----------------------|---------------------------|---------------------|-------------------------------|----------------------|---------------------------------------------------------------|--------------------------------------|
| Mullins et al. 2018 [26]    | Peri-operative blood loss and blood transfusions | NR                        | NR                  | NR                           | NR                   | Primary: (1) TTS; (2) peri-operative change in Hb concentration; (3) blood transfusion; (4) re-operation; (5) 30-day mortality | Primary: (1) no difference in TTS: DOACs (19 h) vs no-DOACs (19 h); (2) no difference in peri-operative change in Hb concentration: DOACs (23 g/L) vs no-DOACs (23 g/L); (3) no difference in blood transfusion: DOACs (18%) vs no-DOACs (10%); (4) no difference in re-operation: DOACs (5%) vs no-DOACs (n=0%); (5) No difference in 30-day mortality: DOACs (2%) vs no-DOACs (8%) |
| Rostagno et al. 2021 [41]   | Need for blood transfusion | NR                        | NR                  | NR                           | NR                   | Primary: (1) TTS longer for DOACs (3.6 h) vs no antiocoagulants (2.2 h); (2) Less DOACs (47%) surgery < 48 h vs no antiocoagulants (80%); (3) No difference in LOS: DOAC (14 days) vs no antiocoagulants (14.6 days); (4) No difference for blood transfusion: DOAC (46%) vs no antiocoagulants (41%); (5) No difference in mortality: DOACs (1.5%) vs no antiocoagulants (3.4%); (6) No difference in intra-operative complications (7) No difference in post-operative complications, except for anaemia (Hb < 8.0 g/dl): DOACs (37%) vs no antiocoagulants (12%) |
| Saliba et al. 2020 [44]     | Intra-operative bleeding subjectively estimated by the surgeon | NR                        | Of the 1108 patients with TTS, 69.9% received general anaesthesia and 30.1% received regional anaesthesia | NR               | NR                   | Primary: (1) all-cause in-hospital mortality and mortality at 30-day, 90-day and 1-year Secondary: (1) LOS; (2) TTS within 48 h; (3) blood transfusion; (4) intra-operative bleeding | Primary: (1) compared to no antiocoagulant use, DOACs had lower odds of mortality at 30 and 90 days and at 1 year; (2) Compared to no antiocoagulant use, DOACs and VKAs users had longer LOS; (3) Compared to no antiocoagulant use, no difference in proportion of DOAC or VKA users who received a blood transfusion; (4) Compared to no antiocoagulant use, no difference in intra-operative moderate-severe bleeding for DOAC or VKA users |
| Authors and publication year | Blood loss definition | Time to surgery definition | Type of anaesthesia | Hours prior to surgery DOACs ceased | Use of reversal agents | Health outcome(s) examined (primary and secondary outcomes) | Study findings (primary and secondary outcomes) |
|------------------------------|-----------------------|---------------------------|--------------------|-----------------------------------|----------------------|------------------------------------------------------------|------------------------------------------------|
| Scherman et al. 2019 [45]   | Peri-operative haemoglobin change as the difference between pre- and post-operative Hb levels divided by pre-operative Hb level multiplied by 100 | Time from admission to surgery | NR                 | NR                                | NR                   | Primary: (1) %Hb change; (2) blood transfusions; (3) 30-day and 1-year mortality Secondary: (1) TTS; (2) % of HF surgery within 48 h | Primary: (1) No difference in %Hb change between DOACs and no-anticoagulants: CRIF DOACs (22.6%) and no-anticoagulants (24.0%) and HA DOACs (21.7%) and no anticoagulants (21.0%) (2) No difference for CRIF or HA for blood transfusion rates for DOACs (8.3% & 10.3%, respectively) and no anticoagulants (7.9% & 7.4%, respectively) (3) No difference for CRIF or HA for blood 30-day mortality for DOACs (6.7% & 6.9%, respectively) and no anticoagulants (4.4% & 6.1%, respectively) 1-year mortality was higher for CRIF for DOACs (26.7%) compared to no-anticoagulants (16.1%), but not for HA for DOACs (13.8%) compared to no anticoagulants (21.1%) Secondary: (1) TTS longer for CRIF for DOACs (40.2 h ± 26.9) compared to no anticoagulants (31.2 h ± 22.2) and no difference for HA (DOACs 42.3 h ± 27.3 and no-anticoagulants 36.6 h ± 25.8) (2) No difference in % of HF surgery within 48 h between DOACs and no-anticoagulants: CRIF DOACs (74%) and no anticoagulants (82%) and HA DOACs (74%) and no anticoagulants (78%) Primary: (1) Increased need for blood transfusion for DOACs (38.5%) compared to no anticoagulation (16.4%), ASS (21.6%), PAI (26.7%) or VKA (24.0%) (2) No difference for ASS, PAI, DOAC, no anticoagulation for Hb-difference. Patients on VKA had lower post-operative Hb difference (3) No difference for PAI, DOAC, ASS, VKA, no anticoagulation for post-operative haematoma Secondary: (1) No difference for PAI, DOAC, ASS, VKA, no anticoagulation for 1-year mortality (2) No post-operative complications identified (3) No difference for PAI (8.5 h), DOAC (9.5 h), ASS (7.4 h), VKA (10.0 h), no anticoagulation (8.2 h) for TTS |
| Schuetze et al. 2019 [46]   | Decision for blood transfusion based on Hb < 8 g/dl with accompanying hypertension, tachycardia or dizziness | NR               | NR                 | NR                                | NR                   | Primary: (1) rate of transfusion; (2) pre- to 24 h post-operative Hb difference; (3) post-operative haematoma requiring revision surgery Secondary: (1) 1-year mortality; (2) post-operative complications (i.e., DVT, cardiac infarction, stroke, pneumonia, urinary tract infection, acute renal failure, deep tissue infection; (3) mean TTS | Primary: (1) Increased need for blood transfusion for DOACs (38.5%) compared to no anticoagulation (16.4%), ASS (21.6%), PAI (26.7%) or VKA (24.0%) (2) No difference for ASS, PAI, DOAC, no anticoagulation for Hb-difference. Patients on VKA had lower post-operative Hb difference (3) No difference for PAI, DOAC, ASS, VKA, no anticoagulation for post-operative haematoma Secondary: (1) No difference for PAI, DOAC, ASS, VKA, no anticoagulation for 1-year mortality (2) No post-operative complications identified (3) No difference for PAI (8.5 h), DOAC (9.5 h), ASS (7.4 h), VKA (10.0 h), no anticoagulation (8.2 h) for TTS |
### Table 1 (continued)

| Authors and publication year | Blood loss definition | Time to surgery definition | Type of anaesthesia | Hours prior to surgery DOACs ceased | Use of reversal agents | Health outcome(s) examined (primary and secondary outcomes) | Study findings (primary and secondary) |
|------------------------------|-----------------------|-----------------------------|---------------------|------------------------------------|-----------------------|-------------------------------------------------------------|-------------------------------------------------------------|
| Shani et al. 2021 [53]       | NR                    | Time from arrival in hospital emergency room until surgery | NR                  | NR                                 | NR                    | Primary: (1) TTS <48 h Secondary: (1) TTS; (2) LOS; (3) unadjusted and adjusted 30-day and 6-month mortality | Primary: (1) Lower proportion of DOACs (69.7%) had TTS < 48 h (warfarin: 69.8%) compared to patients not on anticoagulants (89.3%) Secondary: (1) Unadjusted TTS longer for DOACs (1.9 ± 1.6 days) and warfarin (2.0 ± 2.2 days) compared to no anticoagulants (1.3 ± 1.8 days). TSS remained longer for DOACs after adjusting for age, gender and Charlson score (2) LOS longer for DOACs (9.9 ± 9.0 days) and warfarin (9.5 ± 9.3 days) compared to no anticoagulants (8.8 ± 8.6 days) (3) Unadjusted 30-day mortality higher for DOACs (6.0%) and warfarin (10.0%) compared to no anticoagulants (4.2%). Unadjusted 6-month mortality higher for DOACs (16.9%) and warfarin (25.1%) compared to no anticoagulants (13.1%) After adjusting for age, gender and Charlson score, 30-day and 6-month mortality were similar for DOACs vs. no anticoagulants and higher for warfarin compared to DOACs or no anticoagulants |
| Tarrant et al. 2020 [39]     | Peri-operative Hb and admission estimate glomerular filtration rate (eGFR) | TTS from admission and TTS after last DOAC dose (Ts) | General (n = 96 DOACs and n = 55 controls) Neuraxial (n = 15 DOACs and n = 56 controls) | NR                   | NR                    | Primary: (1) 30-day mortality Secondary: (1) Number of packed cells transfused; (2) Post-operative day (POD) 1 Hb; (3) Serious adverse events (SAE) including myocardial infarction, acute renal failure, respiratory failure, cerebrovascular accident, DVT, PE, pneumonia, bacteraemia/sepsis, surgical site infection, post-operative haemorrhage; (4) TTS from admission; (5) Median LOS (Q1-Q3); (6) inpatient mortality | Primary: (1) No difference in 30-day mortality between DOACs (14%) and controls (6.3%) Secondary: (1) Transfusion not reported by DOACs vs. controls (2) POD1 Hb not reported by DOACs vs. controls (3) SAEs not reported by DOACs vs. controls (4) DOACs higher TTS (1.8 ± 1.3 days) vs. controls (1.2 ± 0.7 days) (5) Longer LOS for DOACs [11 (6.5–18) days] vs. controls [6.9 (4.2–11) days] (6) Higher inpatient mortality for DOAC (7.1%) vs. controls (8.9%) |
| Authors and publication year | Blood loss definition | Time to surgery definition | Type of anaesthesia | Hours prior to surgery DOACs ceased | Use of reversal agents | Health outcome(s) examined (primary and secondary outcomes) | Study findings (primary and secondary) |
|-----------------------------|-----------------------|---------------------------|---------------------|------------------------------------|-----------------------|----------------------------------------------------------------|--------------------------------------|
| Tran et al. 2015 [54]       | Estimated intra-operative blood loss from anaesthesia record. Blood transfusions Bleeding events as defined by ISTH criteria | Time from admission to surgery | NR                  | NR                                 | NR                    | Primary: (1) TTS Secondary: (1) Intra-operative blood loss; (2) blood transfusion; (3) bleeding events; (4) DVT or PE; (5) stroke; (6) in-hospital mortality | Primary: (1) Median TTS longer for DOAC and VKA vs. controls (40 h vs. 26.2 h). Longer TTS for DOAC vs. VKA (66.9 h vs. 39 h) Secondary: (1, 2, 3) No difference in major bleeding episodes for DOAC and VKA vs. controls (4) No difference in DVT or PE for DOAC and VKA vs. controls (5) No difference in stroke for DOAC and VKA vs. controls (6) No difference in in-hospital mortality for DOAC and VKA vs. controls |
| Viktil et al. 2019 [55]     | Difference between last Hb measurement before surgery and the first after surgery | Time from admission to surgery | NR                  | NR                                 | NR                    | Primary: (1) 50% of DOAC users had serum concentrations above reference ranges at admission (2) DOACs prolonged elimination half-life (possibly due to reduced renal function and low drug clearance) Secondary: (1) TTS longer for DOAC vs. Warfarin vs. PAI (median 44 vs. 25 vs. 22 h) (2) Hb lower for Warfarin vs. DOACs vs. PAIs. (median 1.1 vs. 2.2 vs. 1.9) | |

NR not reported
Synthesis of the evidence on the impact of pre-operative direct oral anticoagulants on patient health outcomes

CASP Appraisal Checklist questions

| Question                                                                 | Yes | No | Cannot Tell | Not Applicable | Confidence Intervals |
|-------------------------------------------------------------------------|-----|----|-------------|-----------------|----------------------|
| 1. Did the study address a clearly focussed issue?                      |     |    |             |                 |                      |
| 2. Did the authors use an appropriate method to answer their question?  |     |    |             |                 |                      |
| 3. Were the cases recruited in an acceptable way?                       |     |    |             |                 |                      |
| 4. Was the outcome accurately measured to minimise bias?                |     |    |             |                 |                      |
| 5a. Have the authors identified all important confounding factors?      |     |    |             |                 |                      |
| 5b. Have they taken into account the confounding factors in the design and/or analysis? |     |    |             |                 |                      |
| 6a. Was the follow-up of the subjects complete enough?                  |     |    |             |                 |                      |
| 6b. Have the authors taken account of the potential confounding factors in the design and/or in their analysis? |     |    |             |                 |                      |
| 7. How large was the treatment effect?                                  |     |    |             |                 |                      |
| 8. How precise was the estimate of the treatment effect?                |     |    |             |                 |                      |
| 9. Do you believe the results?                                          |     |    |             |                 |                      |
| 10. Can the results be applied to the local population?                 |     |    |             |                 |                      |
| 11. Do the results of this study fit with other available evidence?     |     |    |             |                 |                      |

Discussion

This rapid review identified 21 studies that examined the impact of pre-operative DOAC use on hip fracture patients' health outcomes. Overall, in these studies the effect of DOAC use on hip fracture patient health outcomes compared to patients not taking any anticoagulants was mixed. Compared to patients not taking anticoagulants, in 57.1%...
of studies DOAC users had a longer time to surgery, 40.0% had a longer hospital LOS, 18.2% had a higher proportion of blood transfusions, and 14.3% had a higher proportion of readmissions, where each of these outcomes was examined. No difference was identified in overall blood loss, post-operative complication rates, stroke, or in-hospital, 30-day or 1-year mortality between DOAC users and patients not taking any anticoagulants in studies that examined these patient outcomes.

The advantages of using DOACs are that they are taken orally and are associated with fewer dietary and other medication interactions [10, 23]. DOACs have a fast therapeutic onset, lower complication and monitoring requirements, and are more cost-effective compared to VKAs, such as warfarin [10, 24]. A systematic review and meta-analysis that examined the effect of DOAC or VKA use on time to surgery and mortality for hip fracture patients found that time to surgery was 15.5 h longer for patients taking DOACs than patients not on anticoagulants, with no difference in time to surgery for patients taking DOACs versus VKAs, and that there was no difference in in-hospital mortality for patients taking DOACs compared to patients not on anticoagulants [25].

While this rapid review found that time to surgery was reported as longer for patients using DOACs pre-operatively, whether or not the surgery was conducted within 48 h was only examined by one-third of studies, with five of six studies identifying a lower proportion of surgery conducted within 48 h for patients taking DOACs versus no anticoagulants. Prior research has largely indicated that better health outcomes after hip fracture surgery are associated with surgery that is conducted within 48 h of patient admission [5–8]. In one study, hip fracture surgery for DOAC users within 24 h of admission was not associated with increased blood loss, transfusion rates or 30-day mortality compared to matched patients not taking anticoagulants [26]. However, larger population-based studies are needed to further examine patient outcomes for DOAC users undergoing surgery <24 h after admission.

The current review found no difference in overall blood loss or post-operative complication rates, and only two studies consistently identified higher mortality rates for hip fracture patients taking DOACs versus no anticoagulants. Prior systematic reviews and meta-analyses of health outcomes of DOACs users compared to patients taking VKAs not limited to trauma found that DOAC users had a reduced patient complication and mortality risk, and showed no difference in blood loss [27–30], except for dabigatran which was associated with a higher risk of gastrointestinal bleeding compared to VKAs [31]. That there was no difference found for patients taking DOACs versus no anticoagulants for mortality, post-operative complications or blood loss may stem in part from a delayed time to surgery for patients taking DOACs as surgical teams aim to optimise these patients prior to surgery to achieve the best outcomes possible. Given a randomised controlled trial is unlikely to take place, and there are large clinical hip fracture registries in a number of countries which measure high-level outcomes in hip fracture patients, developing a consensus and monitoring approach for time to surgery for patients taking DOACs may guide practice in the future.

Published reviews and practical guidelines have indicated there is no consensus on an appropriate DOAC free period prior to acute hip fracture surgery [32–34]. The recommended time to surgery in guidelines has ranged from 12 h after the last dose to up to 4 days, depending on half-life of the DOAC and patient renal function [32–35]. Most recommendations on time to surgery for patients pre-operatively taking DOACs have been made for patients undergoing elective surgery [32], and there has been limited examination of DOACs and time to surgery in the acute care setting, such as for hip fracture.

This systematic rapid review has identified that the research evidence surrounding pre-operative DOAC use and time to surgery is mainly derived from retrospective cohort studies conducted at single facilities which describe current varied practice. The review identified limited evidence to support the development of practical clinical guidelines on the management of hip fracture patients taking DOACs. These studies indicate that almost two-thirds of DOAC users are delayed to hip fracture surgery compared to patients not taking any anticoagulants. Whether a delay to surgery for hip fracture patients taking DOACs pre-operatively is justified needs further clarification from robust, large population-based studies [32, 35], along with further pragmatic investigation of the use of reversal agents for DOACs prior to acute hip fracture surgery [36].

This rapid review has also shown there is a need for consistency in the type of health outcomes examined post-hip fracture surgery to determine the effect of DOACs on patient outcomes. This includes providing clear definitions for each health outcome examined, particularly for the measurement of blood loss, noting the hours prior to surgery that DOAC use ceased, the type of anaesthesia used during surgery, and the specific type of post-operative complications examined. In six (33.3%) studies in this review [26, 37–41], a matched comparison group was used or data were matched post hoc, but matching criteria were not consistent across studies, nor were consistent comparator groups used. Where matching was not used, only six (40.0%) studies specified and adjusted for potential covariates [42–47], indicating potential limitations of sample size to conduct regression analyses. In ten (47.6%) studies, there were less than 50 patients taking DOACs.

With the ageing population and the growth of chronic diseases, the use of DOACs in older hip fracture patients is likely to increase [9]. Further pragmatic research is needed.
to examine the impact of pre-operative DOAC use on hip fracture patient health outcomes, including examining patient experience measures along with patient-reported outcome measures, particularly regarding HRQoL and ADLs.

The strengths of this rapid review were that it followed the PRISMA guidelines, it used a comprehensive keyword search strategy involving three databases, a university medical librarian assisted with the development of the keyword search terms, and multiple reviewers were involved in the data extraction phase with high interrater reliability. Any clarifications or disagreements were discussed between reviewers and consensus was obtained. However, there were some limitations of the review. Studies published in non-English languages were excluded, which may result in language bias. The rapid review did not examine clinical trials registries, so any trials currently underway were excluded. Three studies included patients aged <65 years; however the mean patient age in these studies was in the 80s, warranting their inclusion.

Conclusions
This review found limited evidence to support guidelines on the management of hip fracture patients taking DOACs. The effect of DOAC use on hip fracture patient health outcomes compared to patients not taking any anticoagulants was mixed, although patients on DOACs had a longer time to surgery. It highlights the need for robust, population-based studies and the consistent examination of hip fracture surgery health outcomes to determine the most appropriate management of patients with a hip fracture taking a DOAC.

Appendix 1: Search strategy for each database

Medline
“Exp Anticoagulants/” OR “Administration, Oral/” OR “Hip Fractures/su [Surgery]” OR “1 and 3” AND “limit 4 to “all aged (65 and over)” AND “limit 5 to (“middle aged (45 plus years)” OR “all aged (65 and over)”)) AND “limit 6 to (English language and (clinical trial, all)” OR “randomized controlled trial” OR “systematic review”).

Embase
“Exp hip fracture” OR “exp anticoagulant agent” OR “1 and 2” OR “exp postoperative period/” OR “3 and 4” OR “(surgery or surgical).tw.” OR “1 and 6” OR “2 and 7” OR “4 and 8” AND “limit 9 to (English language and (clinical trial or randomized controlled trial))” AND “limit 12 to (English language and yr = “2011–2022”)

Scopus
(TITLE-ABS-KEY (anticoagulant* OR “oral anticoagulant” OR “DOAC*” OR Rivaroxaban OR Apixaban OR Dabigatran OR Edoxaban) AND ABS (“hip fracture” OR “hip surgery”) AND ABS (postoperative* OR mortality OR “time to surgery” OR “length of stay” OR “complication*” OR bleed* OR “blood loss” OR embolism OR thrombosis OR “intensive care*”)) AND (LIMIT-TO (LANGUAGE, “English”)).

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00068-022-01937-8.

Acknowledgements The authors thank Ms Mary Simons, medical research librarian, for their expertise and guidance regarding the development of the search terminology.

Author contributions All authors contributed to the study conception and design. SJ conducted the database searches. SJ and NH conducted abstract, full-text screening and quality reviews. RM appraised the full-text screening and quality review results and conducted the data synthesis. The first draft of the manuscript was written by RM and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding Open Access funding enabled and organized by CAUL and its Member Institutions. This research did not receive any specific Grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials All data generated or analysed during this study are included in this published article.

Code availability Not applicable.

Declarations
Conflict of interest The authors declare they have no conflict of interest.

Ethics approval and consent to participate Not applicable.

Consent for publication Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Sharma S, Mueller C, Stewart R, Veronese N, Vancampfort D, Koyanagi A, Lamb S, Perera G, Stubbs B. Predictors of falls and fractures leading to hospitalization in people with dementia: a representative cohort study. J Am Med Directors Assoc. 2018.

2. Abrahamsson B, Van Staa T, Ariely R, Olson M, Cooper C. Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int. 2009;20:1633–50.

3. Lystad R, Cameron C, Mitchell R. Mortality risk among older Australians hospitalised with hip fracture: a population-based matched cohort study. Arch Osteoporos. 2017;12:67.

4. Dyer S, Crotty M, Fairhall N, Magaziner J, Beaufre L, Cameron I, Sherrington C. A critical review of the long-term disability outcomes following hip fracture. BMC Geriatr. 2017;16:158.

5. Moja L, Piaatti A, Pecoraro V, Ricci C, Virgili G, Salanti G, Ger-magnoli L, Liberati A, Bagni G. Timing matters in hip fracture surgery: patients operated within 48 hours have better outcomes. A meta-analysis and meta-regression of over 190,000 patients. PLoS ONE. 2012;7:e46175.

6. Leer-Salvesen S, Engeset LB, Dybvik E, Furnes O, Kristensen TB, Gjertsen J-E. Does time from fracture to surgery affect mortality and intraoperative medical complications for hip fracture patients? An observational study of 73 557 patients reported to the Norwegian Hip Fracture Register. Bone Joint J. 2019;101:1129–37.

7. Klestil T, Röder C, Cotter T, Winkler B, Nehrer S, Lutz M, Kler-tings I, Wagner G, Gartlehner G, Nussbaumer-Streit B. Impact of timing of surgery in elderly hip fracture patients: a systematic review and meta-analysis. Sci Rep. 2018;8:1–15.

8. Orosz GM, Magaziner J, Hannan EL, Morrison RS, Koval K, Gil- bert M, McLaughlin M, Halm EA, Wang JJ, Litke A. Association of timing of surgery for hip fracture and patient outcomes. JAMA. 2004;291:1738–43.

9. Damanti S, Brahim S, Pasina L. Anticoagulation in frail older people. J Geriatr Cardiol. JGC. 2019;16:844–6.

10. Tararu R, Redcliff C, Williams P, Diament M, Tate A, Maddox J, Wilson F, Eardley W. Use of anticoagulants remains a significant threat to timely hip fracture surgery. Geriatr Orthop Surg Rehabil. 2019;101:1129–37.

11. Cardoso G, Andreotti M, Marko T, Tonon F, Corradi N, Rizzato D, Valenti A, Valpiani G, Massari L. The impact of warfarin on operative delay and 1-year mortality in elderly patients with hip fracture: a retrospective observational study. J Orth Surg Res. 2019;14:1–9.

12. Lott A, Haglin J, Belayneh R, Konda SR, Leucht P, Ego1 KA. Surgical delay is not warranted for patients with hip fractures receiving non-warfarin anticoagulants. Orthopedics. 2019;42:e331–5.

13. National Institute for Health and Care Excellence, The management of hip fracture in adults, 2011, National Institute for Health and Care Excellence; London.

14. Australian and New Zealand Hip Fracture Registry Steering Group. Australian and New Zealand Guideline for Hip Fracture Care, 2014, Australian and New Zealand Hip Fracture Registry Steering Group; Sydney.

15. American Academy of Orthopaedic Surgeons, Management of hip fractures in the elderly. Evidence-based clinical practice guideline, 2014, American Academy of Orthopaedic Surgeons: Rosemont, IL.

16. Borges FK, Bhandari M, Guerra-Farfan E, Patel A, Sigamani A, Umer M, Tiboni ME, del Mar Villar-Casares M, Tandon V, Tomas-Hernandez J. Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial. The Lancet. 2020;395:698–708.

17. Lizaour-Utrilla A, Martinez-Mendez D, Collados-Maestre I, Miralles-Muñoz FA, Marco-Gomez L, Lopez-Prats FA. Early surgery within 2 days for hip fracture is not reliable as healthcare quality indicator. Injury. 2016;47:1530–5.

18. Dauliana Z, Papakostidou I, Varitimidis S, Michalitsis S, Veloni A, Malizos K. Surgical treatment of hip fractures: factors influencing mortality. Hippokratia. 2013;17:252.

19. Fohtung RB, Novak E, Rich MW. Effect of new oral anticoagulants on prescribing practices for atrial fibrillation in older adults. J Am Geriatr Soc. 2017;65:2405–12.

20. Harley N, Dennison E, Cooper C. Osteoporosis: impact on health and economics. Nat Rev Rheumatol. 2010;6:99–105.

21. Critical Appraisal Skills Programme. CASP Cohort study checklist. 2018 [cited 2021 6/10/2021]; Available from: https://casp-uk.net/.

22. Critical Appraisal Skills Programme. CASP case–control study checklist. 2018 [cited 2021 6/10/2021]; Available from: https://casp-uk.net/.

23. Cherubini A, Carrieri B, Marinelli P. Advantages and disadvantages of direct oral anticoagulants in older patients. Geriatr Care. 2018; 4.

24. Liew A, Douketis J. Perioperative management of patients who are receiving a novel oral anticoagulant. Intern Emerg Med. 2013;8:473–84.

25. You D, Xu Y, Ponich B, Ronsksky P, Skeith L, Korley R, Car- rier M, Schneider PS. Effect of oral anticoagulant use on surgical delay and mortality in hip fracture: a systematic review and meta-analysis. Bone Joint J. 2021;103:222–33.

26. Mullins B, Akehurst H, Slattery D, Chesser T. Should surgery be delayed in patients taking direct oral anticoagulants who suffer a hip fracture? A retrospective, case-controlled observational study at a UK major trauma centre. BMJ Open. 2018; 8.

27. Sardar P, Chatterjee S, Chaudhari S, Lip GY. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomised trials. J Am Geriatr Soc. 2014;62:857–64.

28. Sadlon, AH and Tsakiris, DA. Direct oral anticoagulants in the elderly: systematic review and meta-analysis of evidence, current and future directions. Swiss Med Weekly. 2016; 146.

29. Gromonprez M, Steurbaa S, De Backer TL, Petrovic M, Lahousse L. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis. Front Pharmacol. 2020;11:1408.

30. Amin A, Garcia Reeves AB, Li X, Dhamane A, Luo X, Di Fusco M, Nadkarni A, Friend K, Rosenblatt L, Mardejian J. Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure. PLoS ONE. 2019;14:e0213614.

31. Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation. 2015;132:194–204.

32. Papachristos IV, Giannoudis PV. Proximal femur fractures in patients taking anticoagulants. EFORT Open Rev. 2020;5:699–706.

33. Shah R, Sheikh N, Mangwani J, Morgan N, Khairandish H. Direct oral anticoagulants (DOACs) and neck of femur fractures in patients taking anticoagulants. EFORT Open Rev. 2020;5:699–706.

34. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Azzza M, Desteghe L, Haeusler KG, Oidgren J, Reinecke H, Rolda-Schil-ling V. The 2018 European Heart Rhythm Association Practical
Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330–93.

35. Griffiths R, Babu S, Dixon P, Freeman N, Hurford D, Kelleher E, Moppett I, Ray D, Sahota O. Guidelines for the management of hip fractures 2020: Guideline by the Association of Anaesthetists. Anaesthesia. 2021;76:225–37.

36. Chaudhary R, Sharma T, Garg J, Sukhe A, Bledin K, Tantry U, Turagam M, Lakkireddy D, Gurbel P. Direct oral anticoagulants: a review on the current role and scope of reversal agents. J Thromb Thrombolysis. 2020;49:271–86.

37. Franklin NA, Ali AH, Hurley RK, Mir HR, Beltran MJ. Outcomes of early surgical intervention in geriatric proximal femur fractures among patients receiving direct oral anticoagulation. J Orthop Trauma. 2018;32:269–73.

38. King K, Polischuk M, Lynch G, Gergis A, Rajesh A, Shelfoon C, Kattar N, Sriselvakumar S, Cooke C. Early surgical fixation for hip fractures in patients taking direct oral anticoagulation: a retrospective cohort study. Geriatr Orthop Surg Rehabil. 2020; 11.

39. Tarrant SM, Catanach MJ, Sarrami M, Clapham M, Attia J, Balogh ZJ. Direct oral anticoagulants and timing of hip fracture surgery. J Clin Med. 2020;9:2200.

40. Mahmood A, Thornton L, Whittam DG, Maskell P, Hawkes DH, Harrison WJ. Pre-injury use of antplatelet and anticoagulations therapy are associated with increased mortality in a cohort of 1038 hip fracture patients. Injury. 2021;52:1473–9.

41. Rostagno C, Cartei A, Polidori G, Ceccotiglio A, Rubbieri G, Curcio M, Boccaccini A, Peris A, Frisco D. Management of ongoing direct anticoagulant treatment in patients with hip fracture. Sci Rep. 2021;11:1–6.

42. Hourston GJM, Barrett MP, Khan WS, Vindlacheruvu M, McDonnell SM. New drug, new problem: do hip fracture patients taking NOACs experience delayed surgery, longer hospital stay, or poorer outcomes? Hip Int. 2020;30:799–804.

43. Leer-Salvesen S, Dybvik E, Ranhoff AH, Husebo BL, Dahl OE, Engesaeter LB, Gjertsen JE. Do direct oral anticoagulants (DOACs) cause delayed surgery, longer length of hospital stay, and poorer outcome for hip fracture patients? Eur Geriatr Med. 2020;11:563–9.

44. Saliba W, Arbel A, Abu-Full Z, Cohen S, Rennert G, Preis M. Preoperative direct oral anticoagulants treatment and all-cause mortality in elderly patients with hip fracture: a retrospective cohort study. Thromb Res. 2020;189:48–54.

45. Schermann H, Gurel R, Gold A, Maman E, Dolkart O, Steinberg EL, Chechik O. Safety of urgent hip fracture surgery protocol under influence of direct oral anticoagulation medications. Injury. 2019;50:398–402.

46. Schuetze K, Eickhoff A, Dehner C, Gebhard F, Richter PH. Impact of oral anticoagulation on proximal femur fractures treated within 24h—a retrospective chart review. Injury. 2019;50:2040–4.

47. Daugaard C, Pedersen AB, Kristensen N, Johnsen S. Preoperative antithrombotic therapy and risk of blood transfusion and mortality following hip fracture surgery: a Danish nationwide cohort study. Osteoporos Int. 2019;30:583–91.

48. Bruckbauer M, Prexli O, Voelckel W, Ziegler B, Grotke O, Maegle M, Schoch H. Impact of direct oral anticoagulants in patients with hip fractures. J Orthop Trauma. 2019;33:e8–13.

49. Cafaro T, Simard C, Tagalakis V, Koollian M. Delayed time to emergency hip surgery in patients taking anticoagulants. Thromb Res. 2019;184:110–4.

50. Creeper K, Stafford A, Reynolds S, Samida S, P’Ng S, Glennon D, Seymour H, Grove C. Outcomes and anticoagulation use for elderly patients that present with an Acute Hip Fracture: multi-centre, retrospective analysis. Int Med J. 2020.

51. Frenkel Rutenberg T, Velkes S, Vitenberg M, Leader A, Halavy Y, Aranani P, Yassin M, Spectre G. Morbidity and mortality after fragility hip fracture surgery in patients receiving vitamin K antagonists and direct oral anticoagulants. Thromb Res. 2018;166:106–12.

52. Gosch M, Jacobs M, Bail H, Grueninger S, Wicklein S. Outcome of older hip fracture patients on anticoagulation: a comparison of vitamin K-antagonists and Factor Xa inhibitors. Arch Orthop Trauma Surg. 2021;141:637–43.

53. Shani M, Yahalom R, Comaneshter D, Holtzman K, Blickstein D, Cohen A, Lustman A. Should patients treated with oral anticoagulants be operated on within 48 h of hip fracture? J Thromb Thrombolysis. 2021;51:1132–7.

54. Tran T, Delluc A, de Wit C, Petriccich W, Le Gal G, Carrier M. The impact of oral anticoagulation on time to surgery in patients hospitalized with hip fracture. Thromb Res. 2015;136:962–5.

55. Viktil KK, Lehre I, Ranhoff AH, Molden E. Serum concentrations and elimination rates of direct-acting oral anticoagulants (DOACs) in older hip fracture patients hospitalized for surgery: a pilot study. Drugs Aging. 2019;36:65–71.